Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...

Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The results increase “my confidence that this approach has merit,” Lauren Sansing says. More trials are on the way.

Robert F. Kennedy Jr. has called for an alternative type of testing that medical experts say would be unethical.

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Not everyone agrees: one expert says it would be more helpful to consider imaging as a quality measure at the local level.

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

IFB-088 (icerguastat) was safe and significantly slowed disease progression in certain people with ALS in a Phase 2 clinical trial.

Cybin pushes forward with Phase 3 depression trials after posting a narrower loss, while securing a $100M funding program.